公开(公告)号：EP1678121A2

公开(公告)日：2006-07-12

申请号：EP04796442.4

申请日：2004-10-22

申请人： Exelixis, Inc.

发明人： BALY, Deborah, Lynn ,  GALAN, Adam, Antoni ,  IBRAHIM, Mohamed, Abdulkader ,  JAEGER, Christopher ,  KEARNEY, Patrick ,  LEAHY, James, William ,  LEWIS, Gary, Lee ,  MCMILLAN, Kirk ,  NOGUCHI, Robin, Tammie ,  NUSS, John, M. ,  PARKS, Jason, Jevious ,  SCHNEPP, Kevin, Luke ,  SHI, Xian ,  WILLIAMS, Matthew, Alan ,  XU, Wei ,  ZHANG, Wentao

IPC分类号： C07C233/64 ,  C07C275/06 ,  C07C275/28 ,  A61K31/16 ,  A61K31/17

CPC分类号： C07C237/22 ,  C07C275/16 ,  C07C275/34 ,  C07C2602/10 ,  C07D207/16 ,  C07D209/20 ,  C07D209/42 ,  C07D209/44 ,  C07D213/56 ,  C07D213/75 ,  C07D215/48 ,  C07D215/54 ,  C07D217/06 ,  C07D217/22 ,  C07D233/56 ,  C07D233/58 ,  C07D263/32 ,  C07D277/46 ,  C07D277/66 ,  C07D277/82 ,  C07D295/155 ,  C07D295/185 ,  C07D319/20 ,  C07D401/04 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D471/04 ,  C07D495/04 ,  C07D513/04

摘要： The invention provides compounds and methods for inhibition of kinases, such as those of the TAO family, more specifically KIAA1361, TAO, and JIK kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.

公开(公告)号：EP2097419B1

公开(公告)日：2011-05-25

申请号：EP08832770.5

申请日：2008-12-22

申请人： Exelixis, Inc.

发明人： BROWN, S., David ,  DU, Hongwang ,  FRANZINI, Maurizio ,  GALAN, Adam, Antoni ,  HUANG, Ping ,  KEARNEY, Patrick ,  KIM, Moon, Hwan ,  KOLTUN, Elena, S. ,  RICHARDS, Steven, James ,  TSUHAKO, Amy, L. ,  ZAHARIA, Cristiana, A.

IPC分类号： C07D491/04

CPC分类号： C07D491/04

摘要： A compound according to formula I: or a pharmaceutically acceptable salt thereof; wherein R1, R2, R3a, R3b, R3c and R3d are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.

公开(公告)号：EP2097419A1

公开(公告)日：2009-09-09

申请号：EP08832770.5

申请日：2008-12-22

申请人： Exelixis, Inc.

发明人： BROWN, S., David ,  DU, Hongwang ,  FRANZINI, Maurizio ,  GALAN, Adam, Antoni ,  HUANG, Ping ,  KEARNEY, Patrick ,  KIM, Moon, Hwan ,  KOLTUN, Elena, S. ,  RICHARDS, Steven, James ,  TSUHAKO, Amy, L. ,  ZAHARIA, Cristiana, A.

IPC分类号： C07D491/04

CPC分类号： C07D491/04

摘要： A compound according to formula I: or a pharmaceutically acceptable salt thereof; wherein R1, R2, R3a, R3b, R3c and R3d are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.